骨科中的血栓栓塞——观察与实验
Thromboembolism in orthopaedics--observation and experiment.
作者信息
Warwick David
机构信息
Department of Orthopaedic Surgery, Southampton University Hospitals, UK.
出版信息
Ann R Coll Surg Engl. 2002 Mar;84(2):118-21.
Abstract
Surgical science has evolved from the meticulously recorded anatomical and pathological experiments applied by Hunter to the use of large observational studies and randomised clinical trials. These modern epidemiological techniques, supported by appropriate statistics, are helping us to answer many questions in surgery. Perhaps nowhere in surgery have these techniques been applied as thoroughly as in orthopaedic thromboembolism.
摘要
外科学已从亨特所进行的详尽记录的解剖学和病理学实验，发展到运用大型观察性研究和随机临床试验。这些在适当统计学支持下的现代流行病学技术，正帮助我们解答外科学中的诸多问题。或许在外科学领域，这些技术在骨科血栓栓塞方面的应用最为彻底。
相似文献
1
Thromboembolism in orthopaedics--observation and experiment.骨科中的血栓栓塞——观察与实验
Ann R Coll Surg Engl. 2002 Mar;84(2):118-21.
2
Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
Br J Surg. 2006 Mar;93(3):374-5; author reply 375-6. doi: 10.1002/bjs.5363.
3
Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
Br J Surg. 2006 Mar;93(3):375; author reply 375-6. doi: 10.1002/bjs.5364.
4
Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
Br J Surg. 2006 Mar;93(3):374; author reply 375-6. doi: 10.1002/bjs.5362.
5
Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery.低分子量肝素用于预防腹部手术后静脉血栓栓塞症
Br J Surg. 2004 Aug;91(8):965-74. doi: 10.1002/bjs.4639.
6
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?低分子量肝素与口服抗凝剂治疗有症状静脉血栓栓塞症的长期疗效比较：癌症相关死亡率是否存在差异？
J Clin Oncol. 2005 Oct 1;23(28):7248-50; author reply 7250. doi: 10.1200/JCO.2005.01.7897.
7
The status of new anticoagulants.新型抗凝剂的现状。
Br J Haematol. 2006 Jul;134(1):3-19. doi: 10.1111/j.1365-2141.2006.06134.x.
8
The optimal long-term treatment of venous thromboembolism.
Clin Adv Hematol Oncol. 2004 Nov;2(11):729-32.
9
Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.新型口服抗凝药在临床实践中的应用：将临床试验结果转化至骨科和普通外科患者群体
Ann Surg. 2009 Aug;250(2):219-28. doi: 10.1097/SLA.0b013e3181ae6dbe.
10
Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.达肝素：在血栓栓塞性疾病预防和治疗中的药理特性及临床疗效
Eur J Med Res. 2004 Apr 30;9(4):215-24.
本文引用的文献
1
Economics of thromboprophylaxis in total hip replacement surgery.全髋关节置换手术中血栓预防的经济学分析
Pharmacoeconomics. 1997 Jul;12(1):30-41. doi: 10.2165/00019053-199712010-00004.
2
Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial.全髋关节置换术后使用足部泵与低分子量肝素预防深静脉血栓形成的比较。一项前瞻性随机试验。
J Bone Joint Surg Am. 1998 Aug;80(8):1158-66. doi: 10.2106/00004623-199808000-00009.
3
Symptomatic venous thromboembolism after total knee replacement.
J Bone Joint Surg Br. 1997 Sep;79(5):780-6. doi: 10.1302/0301-620x.79b5.7761.
4
Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases.1390例膝关节置换术后致命性肺栓塞的发生率，除高危病例外未进行常规预防性抗凝。
J Arthroplasty. 1997 Sep;12(6):599-602. doi: 10.1016/s0883-5403(97)90131-5.
5
Removing bias in surgical trials.消除外科手术试验中的偏差。
BMJ. 1997 Mar 29;314(7085):916-7. doi: 10.1136/bmj.314.7085.916.
6
7
8
Does total hip arthroplasty predispose to chronic venous insufficiency?
J Arthroplasty. 1996 Aug;11(5):529-33. doi: 10.1016/s0883-5403(96)80105-7.
9
Surrogate end points in clinical trials: are we being misled?临床试验中的替代终点：我们是否被误导了？
Ann Intern Med. 1996 Oct 1;125(7):605-13. doi: 10.7326/0003-4819-125-7-199610010-00011.
10
Better reporting of randomised controlled trials: the CONSORT statement.优化随机对照试验报告：CONSORT声明
BMJ. 1996 Sep 7;313(7057):570-1. doi: 10.1136/bmj.313.7057.570.
Zotero 插件